Trial results

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT05872620 on ClinicalTrials.gov · last registry update 2026-09-04

An unusually large phase 3: 1,613 participants, more than double the 424 typical for the stage. The sponsor logged completion for 8 August 2025. Primary outcome, as filed: Percent Change From Baseline in Body Weight. orforglipron is approved in the US, but not for type 2 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

1,613

Started

2023-06-05

Primary completion

2025-08-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight

Conditions studied

Obesity · Overweight · Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.